DiaSorin

LIAISON® MeMed BV® and LIAISON® BRAHMS PCT® can provide a powerful solution for healthcare systems, delivering a range of benefits that span improved cost savings, antibiotic stewardship and better patient outcomes. LIAISON® MeMed BV® confirms antibiotic need at the point of care with a 99% NPV, while LIAISON® BRAHMS PCT®, the Gold Standard in diagnosing and monitoring Sepsis, helps manage infection and sepsis progression, guiding the use of antibiotic therapy. This diagnostic duo equips your hospital with the tools to transform your antibiotic stewardship program, improving patient safety and driving significant cost reductions.  Diasorin. Your Infection Management partner. #WAAW #AntimicrobialResistance #AntibioticStewardship #LIAISONMeMedBV #LIAISONBRAHMSPCT

We’re excited to share our latest poster at #AMP2024: “Epidemiology of Respiratory Pathogens and the Impact of Seasonality, Patient Demographics, and Diagnostic Testing Approach: A Retrospective Analysis from 2022 to 2023.” Author: Kaisha Gonzalez, PhD, Regional Director of Scientific Affairs at Diasorin   Poster Number: ID40   Date & Time: Friday, November 22nd, 9:15 a.m. - 10:15 a.m. PST Join Kaisha Gonzalez, PhD, Regional Director of Scientific Affairs at Diasorin, as she presents the importance of diagnostic stewardship in respiratory infections. We look forward to seeing you there! See how Diasorin’s respiratory diagnostic tests can streamline your workflow: https://hubs.li/Q02Yr9p60 #RespiratoryHealth #DiagnosticTesting #DiagnosticStewardship #AMP2024

From November 18 to 24, 2024, Diasorin is participating in World Antimicrobial Resistance (AMR) Awareness Week. Our goal is to raise awareness about the global threat of antimicrobial resistance and to promote best practices that help curb the rise and spread of drug-resistant infections. By working together, we can support safer, more effective healthcare for all. #Diasorin #WorldAntimicrobialAwarenessWeek #AntimicrobialResistance #AMR

Healthcare-associated infections (HAIs) are a major threat to vulnerable hospital patients, affecting more than 1 million patients and resulting in thousands of deaths annually in the US. PCR-based molecular testing of patients suspected of HAIs is key to expediting pathogen detection and patient isolation to prevent potentially deadly HAI outbreaks. Learn more about HAIs in the latest ID Transmission by Dr. Ayaz Majid (Director, Product Mangement - Diasorin): https://hubs.li/Q02YfdQG0 Explore Diasorin’s molecular HAI testing menu: https://hubs.li/Q02YfrKM0 #HAI #Cauris #moleculartesting

Evaluating diabetic status is essential for accurate diagnosis and effective management of diabetes—a condition that impacts millions worldwide. At Diasorin, we are dedicated to advancing the prevention, diagnosis, and management of diabetes. Our mission is to empower patients, families, and healthcare providers with the tools and insights they need to tackle diabetes head-on and enhance quality of life. Together, we’re making strides toward a healthier future. #Diasorin #WorldDiabetesDay

We are continuing to build on our legacy blood culture portfolio with the submission of the LIAISON PLEX® Gram-Positive Blood Culture Assay on the sample-to-answer LIAISON PLEX® System. Gram-positive bacteremia accounts for approximately 60% of all positive blood cultures. Optimized treatment is crucial for saving patients’ lives, and assays built with our proprietary NanoGrid technology have been at the forefront of helping clinicians make critical therapeutic decisions in hours, not days.

Today is World Pneumonia Day, a reminder of the significant impact pneumonia has on global health, with high morbidity, mortality, and associated healthcare costs. To combat this serious infectious disease, Diasorin has been providing specific diagnostic tests for many years. This year, we are proud to introduce the LIAISON® Urinary Ag test, a new automated solution that delivers accurate and rapid results, enhancing our efforts in pneumonia diagnosis and in patient management. #Diasorin #WorldPneumoniaDay

When it comes to treating cCMV, early diagnosis is key. Unfortunately, 91% of women are unaware of the risk of CMV—a common herpes virus that is harmless in most healthy adults. When transmitted during pregnancy, CMV may cause hearing loss and long-term developmental issues in newborns. Early diagnosis is key for #healthymothersandbabies. The Simplexa® Congenital CMV Direct assay is the only FDA-cleared test that detects cCMV in both saliva swabs and confirmatory urine samples in newborns, under 21 days of age, to facilitate the accurate detection and diagnosis of cCMV. For better health in moms and babies, visit our extensive menu of best-in-class diagnostic tests to support women and neonatal health on our website: https://hubs.li/Q02XcB5l0 #cCMV #newbornhealth

Stay updated on what may or may not be covered regarding COVID-19 testing now that the pandemic is over, and COVID-19 is no longer a public health emergency.  Whether your patients are covered under Medicare, Medicaid, or private insurance, or just want to know what safety nets are available for those uninsured, check out our blog summarizing what changes to coverage and reimbursement policies you might expect.  Check out our blog: https://hubs.li/Q02Tqz7S0 #HealthcareReimbursement #Diasorin

It’s no secret that clinical labs are facing a perfect storm of challenges: rising costs, staff shortages, and increased demand. Check out our blog summarizing an interview with two Diasorin team members in Medical Laboratory Observer. Learn what solutions they shared regarding what Diasorin offers for optimizing respiratory testing through the customization of syndromic testing. Read the blog: https://hubs.li/Q02W_Tg70 #Diasorin #LIAISONPLEX